Outlook Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Outlook Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Outlook Therapeutics Inc
Rating: 0.72766675
Author: Trendlyne DVM scores

about

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an oph...

0.44 -0.01 (-2.22%)

85.43% Fall from 52W High

611.0K

XNAS Volume

XNAS 10 Mar, 2026 2:25 PM (EDT)

Board Meeting

The next board meeting for Outlook Therapeutics Inc is on 11 Mar 2026 for the purpose of Outlook Therapeutics Inc Annual General Meeting for 2026 See details

Not Eligible

Expensive Valuation

1.7 / 100

Technically Bearish

27.4 / 100

1Yr Price target upside is 1123%

4 analysts

Outlook Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Outlook Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an oph...

85.43% Fall from 52W High

SWOT Analysis

Outlook Therapeutics Inc Live Price Chart